View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsFlowr 将来の成長Future 基準チェック /06現在、 Flowrの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長31.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • May 31Price target decreased to CA$0.04Down from CA$0.08, the current price target is provided by 1 analyst. New target price is 11% below last closing price of CA$0.045. Stock is down 86% over the past year. The company posted a net loss per share of CA$0.23 last year.Price Target Changed • Apr 27Price target decreased to CA$0.08Down from CA$0.10, the current price target is provided by 1 analyst. New target price is 45% above last closing price of CA$0.055. Stock is down 81% over the past year. The company is forecast to post a net loss per share of CA$0.08 next year compared to a net loss per share of CA$0.95 last year.Major Estimate Revision • Dec 06Consensus revenue estimates fall to CA$12.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CA$14.0m to CA$12.0m. Forecast losses increased from -CA$0.34 to -CA$0.36 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$0.10 unchanged from last update. Share price fell 24% to CA$0.065 over the past week.Price Target Changed • Jul 15Price target decreased to CA$0.68Down from CA$0.97, the current price target is an average from 2 analysts. New target price is 200% above last closing price of CA$0.23. Stock is down 58% over the past year.Price Target Changed • Dec 05Price target lowered to CA$1.15Down from CA$1.29, the current price target is an average from 4 analysts. The new target price is 135% above the current share price of CA$0.49. As of last close, the stock is down 77% over the past year.Major Estimate Revision • Dec 01Analysts lower revenue estimates to CA$9.21mThe 2020 consensus revenue estimate decreased from CA$11.7m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -CA$0.22 to -CA$0.26 for the same period. The Pharmaceuticals industry in Canada is expected to see a 23% decline in net income next year. The consensus price target was lowered from CA$1.29 to CA$1.28. Share price is up 16% to CA$0.47 over the past week.すべての更新を表示Recent updatesお知らせ • Feb 18The Flowr Corporation Requests to Delist from the TSX Venture ExchangeThe Flowr Corporation (the “Company”) announced that in connection with the closing of its previously announced sale transaction under the Companies’ Creditors Arrangement Act (Canada) (the “CCAAProceedings”), all of the former officers and directors of the Company have resigned and the Court has expanded the powers of Ernst & Young Inc., which acts as the Court appointed Monitor under the CCAA Proceedings (the “CCAA Monitor”) in order to oversee the remaining activities in the CCAA Proceedings including any distribution to creditors and the winding down of operations. On account of the Company having no operating business and having sold substantially all of its assets, as well as the resignation of its management and board of directors, the CCAA Monitor has requested that the common shares of the Company be delisted from the TSX Venture Exchange.お知らせ • Feb 04Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 5.12 million.1000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million on November 1, 2022. The transaction is subject to approval by the Ontario Superior Court of Justice,receipt of regulatory approval, the Stalking Horse Purchase Agreement being determined to be the successful bid in the SISP and the Court granting both an order approving the Stalking Horse Purchase Agreement and an Approval and Vesting Order. In the event the Purchaser is not the winning bidder under any such auction, the Stalking Horse Purchase Agreement will be terminated, and the Purchaser will be entitled to payment of a break-up fee in the amount of CAD 0.185 million following closing of the winning bid. The Purchase Price will be satisfied through (a) a credit bid of the DIP Loan in a principal amount of CAD 2 million, plus the Closing DIP Amount, if any, and any accrued and unpaid interest, expenses, fees and other amounts thereon, (b) a cash amount equal to the Purchase Price less the Credit Bid in cash, a portion of which may be payable in non-cash consideration in certain circumstances, and (c) the assumption of the Assumed Liabilities. On December 1, 2022 1000343100 Ontario Inc. has entered into a definitive purchase agreement to acquire all of the issued and outstanding shares in the capital of The Flowr Group (Okanagan) Inc. The purchase price payable by 1000343100 Ontario Inc. for the Purchased Shares pursuant to the Purchase Agreement shall be CAD 5,115,000, being equal to (a) CAD4,015,000, and (b) common shares in the capital of Avant with a value of CAD 1.1 million based on the deemed price per Avant Share equal to a 15% discount to the volume weighted average price per Avant Share on the Toronto Stock Exchange for the 10 consecutive trading days preceding the close of trading on the trading day before the Closing Date. The Transaction is expected to close within Q1 of 2023. Jane Dietrich, Jeremy Bornstein, Jeffrey Mikelberg, Kori Williams, Chandimal Nicholas, Jonathan Sherman of Cassels is representing Avant. Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 7.7 million on February 3, 2023. The aggregate revised purchase price consists of (a) CAD 3.85 million payable in cash and (b) 7,402,186 common shares in the capital of Avant; plus (i) the amount of the Closing DIP Loan (to the extent not otherwise repaid), to an aggregate of CAD 2.5 million; and (ii) the value of the Assumed Liabilities, subject to certain adjustments (collectively, the “Purchase Price”). On January 31, 2023, the DIP Term Sheet was amended and the principal amount of the DIP Loan was increased by CAD 0.5 million to an aggregate of CAD 2.5 million.お知らせ • Nov 021000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million.1000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million on November 1, 2022. The transaction is subject to approval by the Ontario Superior Court of Justice,receipt of regulatory approval, the Stalking Horse Purchase Agreement being determined to be the successful bid in the SISP and the Court granting both an order approving the Stalking Horse Purchase Agreement and an Approval and Vesting Order. In the event the Purchaser is not the winning bidder under any such auction, the Stalking Horse Purchase Agreement will be terminated, and the Purchaser will be entitled to payment of a break-up fee in the amount of CAD 0.185 million following closing of the winning bid. The Purchase Price will be satisfied through (a) a credit bid of the DIP Loan in a principal amount of CAD 2 million, plus the Closing DIP Amount, if any, and any accrued and unpaid interest, expenses, fees and other amounts thereon, (b) a cash amount equal to the Purchase Price less the Credit Bid in cash, a portion of which may be payable in non-cash consideration in certain circumstances, and (c) the assumption of the Assumed Liabilities.お知らせ • Oct 18The Flowr Corporation Announces Resignation of Stephen Arbib as DirectorThe Flowr Corporation announced that Stephen Arbib has resigned from the board of directors of the Company effective immediately.お知らせ • Oct 01The Flowr Corporation Announces the Resignation of Joanne Lee from the Board of DirectorsThe Flowr Corporation announced that Joanne Lee has resigned from the board of directors in order to pursue other opportunities.Board Change • Sep 24High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Director Tom Flow is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Aug 11+ 1 more updateThe Flowr Corporation Announces Management ChangesThe Flowr Corporation announced leadership and governance changes with the appointments of Darren Karasiuk to the role of Chief Executive Officer and Director and the additions of Stephen Arbib as Chairman and Marvin Singer to the Board of Directors. Tom Flow, who has acted as Interim CEO of Flowr since March, remains on the Board along-side incumbents Joanne Lee and Ryan Roebuck. Darren is a veteran of the cannabis industry with experience and success in all aspects of the value chain. Prior to joining Flowr, Darren was CEO of Nova Cannabis, one of Canada’s larger cannabis retailers, disrupting the industry with the launch of the Value Buds banner. Prior to Nova, Darren was Chief Commercial Officer at Aurora Cannabis, leading it to become market share leader in Canada’s recreational and medical markets as well as in Europe. Before joining Aurora, Darren was VP Strategy and later SVP and GM, Recreational for MedReleaf, a Canadian LP sold to Aurora in 2018. Stephen Arbib is a Canadian entrepreneur, philanthropist and significant shareholder of Flowr. Mr. Arbib is the founder?and CEO of Momentum Solutions, one of the world’s leading logistics and life support service providers, specializing in humanitarian and emergency operations for government agencies, militaries and non-profit organizations. Momentum provides services from passenger and cargo air movements, freight forwarding, construction equipment leasing, labour force and staffing and housing. In 2013, Mr. Arbib founded?MedReleaf, the first ISO 9001 certified cannabis producer in North America and one of the global leaders in the production and research of medicinal cannabis which was sold to Aurora for CAD 3.2Bn in 2018. Mr. Arbib is the Director of the Arbib Foundation, a charitable foundation that allocates personal funds to charities across the globe. Marvin Singer currently works as a director and corporate consultant. Mr. Singer has acted as a consultant to private and public companies since January 2020, after retiring from practising corporate and securities law for 40 years, most recently as a senior partner in the international law firm of Norton Rose Fulbright Canada LLP from 2005 until 2019. Mr. Singer has extensive experience in equity and debt financings, governance, and mergers and acquisitions. Mr. Singer served as a director for Nova Cannabis and is currently a director of Osino Resources Corp. and Psyence Group Inc.お知らせ • Jul 29Hawthorne Canada Limited completed the acquisition of KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR).Hawthorne Canada Limited entered into an agreement to acquire KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR) for CAD 16 million on February 16, 2022. The consideration will be paid as follows: 1) an initial cash payment of CAD 3.0 million; 2) full extinguishment of the principal amount outstanding under the existing loan agreement between Flowr and Hawthorne for the construction of the KRS Facility on closing, currently at approximately CAD 12 million; and 3) the balance of the purchase price paid in cash upon closing. The KRS Sale is expected to close in Q2 2022 and is subject to certain closing conditions, including receipt of all necessary regulatory and third-party approvals. The Flowr Corporation (TSXV:FLWR) completed the acquisition of KRS Facility in Kelowna on July 27, 2022. The Company is using the proceeds from the sale of this non-core asset to reduce the outstanding principal debt under its ATB led credit facility to CAD 1 million.お知らせ • Jul 13The Flowr Corporation Announces Resignation of Noel Biderman as DirectorThe Flowr Corporation announces the resignation of Noel Biderman from the Board of Directors who is departing in order to pursue other opportunities.お知らせ • Jul 05The Flowr Corporation Announces Resignation of DirectorsThe Flowr Corporation announced the resignation of Maurice Levesque and Don Duet from the Board of Directors who are departing in order to pursue other opportunities.お知らせ • Jul 01The Flowr Corporation, Annual General Meeting, Sep 07, 2022The Flowr Corporation, Annual General Meeting, Sep 07, 2022.お知らせ • Jun 24The Flowr Corporation Announces Headcount ReductionThe Flowr Corporation announced the completion of a significant corporate headcount reduction resulting in over $4 million in cost savings per year as well as an agreement to sell a non-core asset for aggregate gross proceeds of $3.4 million. The Company has completed a headcount reduction necessary in order to flatten its organizational structure and right-size SG&A with revenue. The Company has eliminated 40% of its workforce, largely in senior and middle management, resulting in an anticipated annual savings of over $4 million.Reported Earnings • Jun 01First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: CA$0.01 loss per share (up from CA$0.025 loss in 1Q 2021). Revenue: CA$3.46m (down 9.7% from 1Q 2021). Net loss: CA$5.37m (loss narrowed 35% from 1Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 188%. Over the next year, revenue is forecast to grow 25%, compared to a 92% growth forecast for the industry in Canada.Price Target Changed • May 31Price target decreased to CA$0.04Down from CA$0.08, the current price target is provided by 1 analyst. New target price is 11% below last closing price of CA$0.045. Stock is down 86% over the past year. The company posted a net loss per share of CA$0.23 last year.Board Change • May 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 31The Flowr Corporation Announces Impairment Charges for the First Quarter Ended March 31, 2022The Flowr Corporation announced impairment charges for the first quarter ended March 31, 2022. For the period, the company recorded impairment charges totaling CAD 29,000.お知らせ • May 21The Flowr Corporation Announces Impairment Charges for the Fourth Quarter Ended December 31, 2021The Flowr Corporation announced impairment charges for the fourth quarter ended December 31, 2021. For the period, the company reported Impairment of assets of CAD 57,096,000 compared to CAD 83,979,000 a year ago.お知らせ • May 03+ 1 more updateCannahealth Limited completed the acquisition of Holigen Limited from The Flowr Corporation (TSXV:FLWR).Cannahealth Limited entered into a definitive agreement to acquire Holigen Limited from The Flowr Corporation (TSXV:FLWR) for CAD 33.3 million on April 19, 2022. Under the transaction, Cannahealth will acquire 1200 shares of Holigen and the receivables owed by Holigen Limited to The Flowr Corporation. The total consideration payable is approximately CAD 35 million consisting of CAD 3.75 million in cash, 1.9 common shares in the capital of Akanda Corp. (NasdaqCM:AKAN), parent of Cannahealth and the indirect assumption of RPK’s indebtedness of approximately CAD 5.1 million. The purchase price will be paid on the closing date, and it was agreed that CAD 1.00 of the purchase price will allocated to the shares, and the balance of the purchase price will be allocated to the purchased receivables. In addition, at least CAD 0.834 million of interim funding will be provided by Cannahealth to Holigen which has already been received by Flowr. In a related transaction, Akanda has agreed to subscribe for CAD 1 million of common shares in the capital of Flowr at a price per share of CAD 0.07 per share. As part of the transaction, Flowr has agreed to provide transition services to Akanda and Holigen for a period of at least 90 days after the closing of the transaction. The transaction is subject to regulatory approvals. The transaction was overseen by an independent committee of directors of Flowr and was unanimously approved by the Independent Committee as well as the board of directors of each of Flowr and Akanda. At the closing of the transaction, which is expected to be in the second quarter of 2022. The deal would give Flowr a significant amount of cash on closing to solidify its balance sheet and also preserve the upside related to its European operations. Hyperion Capital Inc. acted as fairness opinion provider to the Independent Committee. In connection with the transaction, Holigen will pay an advisory fee to an arm’s length third party equal to 7% of the purchase price, 50% of which is payable in cash and 50% of which is payable in consideration shares to be received by Holigen. Eric Foster of Dentons Canada LLP acted as legal advisor for Akanda Corp. Jeff Hergott of Wildeboer Dellelce LLP acted as legal advisor for The Flowr Corporation. Cannahealth Limited completed the acquisition of Holigen Limited from The Flowr Corporation (TSXV:FLWR) on May 2, 2022.Price Target Changed • Apr 27Price target decreased to CA$0.08Down from CA$0.10, the current price target is provided by 1 analyst. New target price is 45% above last closing price of CA$0.055. Stock is down 81% over the past year. The company is forecast to post a net loss per share of CA$0.08 next year compared to a net loss per share of CA$0.95 last year.Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 21+ 1 more updateCannahealth Limited entered into a definitive agreement to acquire Holigen Limited from The Flowr Corporation (TSXV:FLWR) for CAD 34.1 million.Cannahealth Limited entered into a definitive agreement to acquire Holigen Limited from The Flowr Corporation (TSXV:FLWR) for CAD 34.1 million on April 19, 2022. The total consideration payable is approximately CAD 35 million consisting of: (i) CAD 3.5 million in cash; (ii) 1.9 common shares in the capital of Akanda currently valued at $10.30 (CAD 12.98) based on the closing price of the consideration shares on April 19, 2022; (iii) the indirect assumption by Akanda of RPK’s indebtedness of approximately CAD 5.1 million; and (iv) at least CAD 0.834 million of interim funding to Holigen which has already been received by Flowr. In addition, Akanda has agreed to subscribe for CAD 1 million of common shares in the capital of Flowr at a price per share of CAD 0.07 per share. As part of the transaction, Flowr has agreed to provide transition services to Akanda and Holigen for a period of at least 90 days after the closing of the transaction. The transaction is subject to regulatory approvals. The transaction was overseen by an independent committee of directors of Flowr and was unanimously approved by the Independent Committee as well as the board of directors of each of Flowr and Akanda. At the closing of the transaction, which is expected to be in the second quarter of 2022. The deal would give Flowr a significant amount of cash on closing to solidify its balance sheet and also preserve the upside related to its European operations. Hyperion Capital Inc. acted as fairness opinion provider to the Independent Committee. In connection with the transaction, Holigen will pay an advisory fee to an arm’s length third party equal to 7% of the purchase price, 50% of which is payable in cash and 50% of which is payable in consideration shares to be received by Holigen.お知らせ • Feb 19Hawthorne Canada Limited entered into an agreement to acquire KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR) for $16 million.Hawthorne Canada Limited entered into an agreement to acquire KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR) for $16 million on February 18, 2022. The consideration will be paid as follows: 1) an initial cash payment of $3.0 million; 2) full extinguishment of the principal amount outstanding under the existing loan agreement between Flowr and Hawthorne for the construction of the KRS Facility on closing, currently at approximately $12 million; and 3) the balance of the purchase price paid in cash upon closing. The KRS Sale is expected to close in Q2 2022 and is subject to certain closing conditions, including receipt of all necessary regulatory and third-party approvals.Major Estimate Revision • Dec 06Consensus revenue estimates fall to CA$12.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CA$14.0m to CA$12.0m. Forecast losses increased from -CA$0.34 to -CA$0.36 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$0.10 unchanged from last update. Share price fell 24% to CA$0.065 over the past week.Reported Earnings • Dec 01Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2021 results: CA$0.02 loss per share (up from CA$0.073 loss in 3Q 2020). Net loss: CA$8.77m (loss narrowed 9.7% from 3Q 2020). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 100%. Earnings per share (EPS) surpassed analyst estimates by 100%. Over the next year, revenue is forecast to grow 149%, compared to a 140% growth forecast for the industry in Canada.Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$7.20m (loss widened 47% from 2Q 2020).お知らせ • Aug 21+ 1 more updateHealth Canada Grants a Research License to The Flowr CorporationThe Flowr Corporation announced that it has been granted a research license by Health Canada. The research license allows the Company to distribute and administer its cannabis for research purposes and to test and review its products based on taste, sight, smell and touch. The Company will utilize this research license in the research and development of novel product offerings.お知らせ • Jul 20The Flowr Corporation announced that it has received CAD 7.014 million in fundingOn July 19, 2021, The Flowr Corporation (TSXV:FLWR) closed the transaction.お知らせ • Jul 16The Flowr Corporation announced that it expects to receive CAD 7.014 million in fundingThe Flowr Corporation announced a private placement of 33,400,000 units at a price of CAD 0.21 per unit for gross proceeds of CAD 7,014,000 on July 15, 2021. Each unit will consist of one common share and one common share purchase warrant, Each warrant will be exercisable into one common share at an exercise price of CAD 0.26 per warrant share at any time for a period of 42 months following the closing date of the transaction. The company will pay CAD 490,000 as finders' fees and issue 2,000,400 broker warrants. Each broker warrant will be exercisable into one unit at the issue price for a period of 36 months from the closing of the transaction. The transaction is expected to close on or about July 20, 2021, subject to the satisfaction of customary closing conditions and the receipt of regulatory approvals, including the approval of the TSX Venture Exchange. The comapny entered into a securities purchase agreement with a purchaser.Price Target Changed • Jul 15Price target decreased to CA$0.68Down from CA$0.97, the current price target is an average from 2 analysts. New target price is 200% above last closing price of CA$0.23. Stock is down 58% over the past year.お知らせ • Apr 29Rodeo Capital Limited entered into an agreement to acquire TCann Pty Ltd. from The Flowr Corporation (TSXV:FLWR) for AUD 0.50 million.Rodeo Capital Limited entered into an agreement to acquire TCann Pty Ltd. from The Flowr Corporation (TSXV:FLWR) for AUD 0.50 million on April 28, 2021. Hyperion Capital Inc. acted as financial advisor to The Flowr Corporation.お知らせ • Mar 17The Flowr Corporation has completed a Composite Units Offering in the amount of CAD 15.3 million.The Flowr Corporation has completed a Composite Units Offering in the amount of CAD 15.3 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 30,000,000 Price\Range: CAD 0.51 Discount Per Security: CAD 0.0357 Transaction Features: Regulation SIs New 90 Day High Low • Mar 06New 90-day low: CA$0.31The company is down 37% from its price of CA$0.49 on 04 December 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 30% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.00 per share.Is New 90 Day High Low • Feb 11New 90-day high: CA$0.60The company is up 33% from its price of CA$0.45 on 12 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 109% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.22 per share.お知らせ • Feb 05The Flowr Corporation Partners with ROSE Lifescience IncThe Flowr Corporation announced that it has entered the Province of Quebec with its first commercial orders for its BC Pink Kush and its new strain BC Black Cherry. Flowr has shipped dried cannabis flower for the first time into the Quebec market through a distribution partnership with ROSE LifeScience Inc. (“ROSE”). Flowr entered into a Sales, Marketing and Distribution Agreement with ROSE in April 2020 and obtained its Autorité des marchés publics approval to operate in the Province of Quebec in August 2020.お知らせ • Jan 24The Flowr Corporation announced that it expects to receive CAD 1 million in fundingThe Flowr Corporation (TSXV:FLWR) announced a non-brokered private placement of 3,333,333 common shares at a price of CAD 0.3 per share for gross proceeds of up to CAD 1,000,000 led by certain directors, officers and insiders on January 22, 2021. The transaction is subject to approval of the TSX Venture Exchange.分析記事 • Jan 18Flowr's (CVE:FLWR) Stock Price Has Reduced 79% In The Past YearIt's not a secret that every investor will make bad investments, from time to time. But serious investors should think...お知らせ • Jan 06Flowr and Hawthorne Canada Jointly Announce the Completion of the World’S First Cannabis Research and Development Facility of Its KindNorth America’s first research and development facility dedicated to advancing cannabis cultivation techniques and systems has been completed by The Flowr Corporation and Hawthorne Canada Limited . Hawthorne is a subsidiary of the Hawthorne Gardening Company division of The Scotts Miracle-Gro Company. Scotts Miracle-Gro is the world’s leading marketer of branded consumer lawn and garden products and indoor growing solutions. Flowr cultivates and sells premium cannabis to medical and adult-use markets in Canada, Europe and Australia.Is New 90 Day High Low • Jan 01New 90-day low: CA$0.33The company is down 22% from its price of CA$0.41 on 02 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 60% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.55 per share.お知らせ • Dec 26The Flowr Corporation Announces CEO ChangesThe Flowr Corporation announced In 2021, Vinay Tolia, Chief Executive Officer of Flowr, will be stepping down from his role as Chief Executive Officer and will be relocating to the United States for personal reasons. He will stay with the Company through the end of February to ensure a smooth transition. Mr. Tolia will remain on the Board of Directors. The current President of Flowr, Lance Emanuel, will lead the Company as Interim Chief Executive Officer. Lance Emanuel joined Flowr in January 2019. Lance has been building seed and early-stage companies into multi-million-dollar enterprises while overseeing critical aspects of business operations in highly regulated markets for more than a decade. He has a wealth of experience in the management of sales, marketing, product management, R&D, technology, legal, compliance and regulatory affairs as well as in procuring both debt and equity financing and creating large scale strategic partnerships. He holds a BBA, with distinction, from the University of Michigan’s Ross School of Business and a Juris Doctor from the Benjamin N. Cardozo School of Law in New York City.お知らせ • Dec 25+ 1 more updateThe Flowr Corporation Announces Board AppointmentThe Flowr Corporation announced announce new appointments to the Board of Directors which include Jörg Cieslok, Michael Galego, Vincent Gasparro and Joanne Lee. In addition, Stephen Arbib, Jonathan Goldman and Francisco Ortiz von Bismarck have been appointed as observers to the Board of Directors. The Board of Directors will continue to be led by current Chairman of the Board & Chief Strategist, Steve Klein. These new appointees join the following directors: Steve Klein (Chair), Vinay Tolia, Thomas Flow, Don Duet and Maurice Levesque. Jörg Cieslok is an executive with few peers in the world of out-of-home media. Known for his industry foresight, out-of-the-box thinking, and sales and marketing strategy, Mr. Cieslok has changed the landscape of out-of-home media in Canada over the course of a 30-year career. By embracing creativity and innovation, he takes advertising campaigns from conceptual ideas to experiential media placements. Jörg was the recipient of the prestigious 2017 CVCA Private Equity deal of the year award for the sale of Cieslok Media to Bell Media. Michael Galego is an executive, lawyer and corporate director with extensive M&A and corporate finance experience. Mr. Galego is currently CEO of Apolo Capital Advisory Corp. and sits on the board of directors of several public and private companies. Mr. Galego was a co-founder and director of ICC Labs Inc. and was integral in its sale to Aurora Cannabis Inc. in November 2018. Vincent Gasparro is currently the Managing Director, Corporate Development & Clean Energy Finance, at Vancity Community Investment Bank. From November 2018 to March 2020, he was the Principal Secretary in the Office of the Mayor of Toronto where he had specific public policy responsibilities including matters related to Toronto Hydro, Toronto Parking Authority, Toronto Global, Toronto Community Housing, CreateTo and the Toronto Police Service. Joanne Lee is a seasoned business executive with strong Operations, Logistics and Procurement expertise, underpinned by extensive financial and M&A experience. She has held key roles in the Healthcare, Consumer Packaging, Polymer and Chemical sectors. As a proven organizational change leader, Ms. Lee has led teams through challenging turnarounds as well as significant business enhancements that have led to increased profitability. Ms. Lee joined Premier Candle Corporation (PCC) in 2009 as General Manager leading the corporation’s division.お知らせ • Dec 19The Flowr Corporation Announces Strategic Warehousing Agreement with Tilray, IncThe Flowr Corporation announced strategic warehousing agreement with Tilray, Inc. whereby the parties have agreed to the storage and warehousing of E.U. GMP certified medical cannabis at the Company's Sintra facility in Portugal. The parties will undertake to develop a collaborative approach with a view to leverage each party's E.U. GMP certified facilities in Portugal to store and warehouse medicinal cannabis products for the European market. The commercial terms of the agreement were not disclosed.Is New 90 Day High Low • Dec 12New 90-day low: CA$0.35The company is down 26% from its price of CA$0.48 on 11 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 49% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$8.06 per share.Price Target Changed • Dec 05Price target lowered to CA$1.15Down from CA$1.29, the current price target is an average from 4 analysts. The new target price is 135% above the current share price of CA$0.49. As of last close, the stock is down 77% over the past year.Major Estimate Revision • Dec 01Analysts lower revenue estimates to CA$9.21mThe 2020 consensus revenue estimate decreased from CA$11.7m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -CA$0.22 to -CA$0.26 for the same period. The Pharmaceuticals industry in Canada is expected to see a 23% decline in net income next year. The consensus price target was lowered from CA$1.29 to CA$1.28. Share price is up 16% to CA$0.47 over the past week.Reported Earnings • Nov 27Third quarter 2020 earnings released: CA$0.07 loss per shareThird quarter 2020 results: Net loss: CA$9.72m (loss narrowed 36% from 3Q 2019).Analyst Estimate Surprise Post Earnings • Nov 27Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 0.1%. Earnings per share (EPS) exceeded analyst estimates by 133%. Over the next year, revenue is forecast to grow 600%, compared to a 136% growth forecast for the Pharmaceuticals industry in Canada.分析記事 • Nov 26The Flowr Corporation (CVE:FLWR) Analysts Are More Bearish Than They Used To BeToday is shaping up negative for The Flowr Corporation (CVE:FLWR) shareholders, with the analysts delivering a...お知らせ • Nov 17The Flowr Corporation to Report Q3, 2020 Results on Nov 24, 2020The Flowr Corporation announced that they will report Q3, 2020 results on Nov 24, 2020お知らせ • Oct 27Andrew Teehan to Leave The Flowr Corporation as General Counsel, Effective October 28, 2020The Flowr Corporation announced that Andrew Teehan its General Counsel is leaving the Company on October 28, 2020 to pursue an opportunity outside of the cannabis industry.Price Target Changed • Oct 21Price target lowered to CA$1.45Down from CA$1.70, the current price target is an average from 4 analysts. The new target price is 205% above the current share price of CA$0.47. As of last close, the stock is down 82% over the past year.Is New 90 Day High Low • Oct 01New 90-day low: CA$0.39The company is down 32% from its price of CA$0.57 on 03 July 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$8.02 per share.お知らせ • Aug 19The Flowr Corporation to Report Q2, 2020 Results on Aug 26, 2020The Flowr Corporation announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 26, 2020分析記事 • Jul 21How Many The Flowr Corporation (CVE:FLWR) Shares Did Insiders Buy, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Flowr は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:FLWR.H - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202212-95-8-7N/A6/30/202213-99-10-8N/A3/31/202212-84-15-14N/A12/31/202112-86-27-25N/A9/30/202110-118-32-29N/A6/30/202110-120-34-28N/A3/31/202110-122-39-27N/A12/31/20208-126-40-25N/A9/30/20206-47-65-36N/A6/30/20204-53-79-39N/A3/31/20204-36-84-41N/A12/31/20195-31-87-35N/A9/30/20198-14-63-22N/A6/30/20197-4-46-16N/A3/31/20194-19-32-9N/A12/31/20183-15-25-10N/A9/30/2018N/A-11-23-7N/A6/30/2018N/A-6-19-5N/A3/31/2018N/A-4-16-4N/A12/31/2017N/A-2-11-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: FLWR.Hの予測収益成長が 貯蓄率 ( 1.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: FLWR.Hの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: FLWR.Hの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: FLWR.Hの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: FLWR.Hの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: FLWR.Hの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/01/14 23:05終値2022/10/17 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋The Flowr Corporation これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関David KideckelATB CormarkNoel AtkinsonClarus Securities Inc.Owen BennettJefferies LLC1 その他のアナリストを表示
Price Target Changed • May 31Price target decreased to CA$0.04Down from CA$0.08, the current price target is provided by 1 analyst. New target price is 11% below last closing price of CA$0.045. Stock is down 86% over the past year. The company posted a net loss per share of CA$0.23 last year.
Price Target Changed • Apr 27Price target decreased to CA$0.08Down from CA$0.10, the current price target is provided by 1 analyst. New target price is 45% above last closing price of CA$0.055. Stock is down 81% over the past year. The company is forecast to post a net loss per share of CA$0.08 next year compared to a net loss per share of CA$0.95 last year.
Major Estimate Revision • Dec 06Consensus revenue estimates fall to CA$12.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CA$14.0m to CA$12.0m. Forecast losses increased from -CA$0.34 to -CA$0.36 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$0.10 unchanged from last update. Share price fell 24% to CA$0.065 over the past week.
Price Target Changed • Jul 15Price target decreased to CA$0.68Down from CA$0.97, the current price target is an average from 2 analysts. New target price is 200% above last closing price of CA$0.23. Stock is down 58% over the past year.
Price Target Changed • Dec 05Price target lowered to CA$1.15Down from CA$1.29, the current price target is an average from 4 analysts. The new target price is 135% above the current share price of CA$0.49. As of last close, the stock is down 77% over the past year.
Major Estimate Revision • Dec 01Analysts lower revenue estimates to CA$9.21mThe 2020 consensus revenue estimate decreased from CA$11.7m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -CA$0.22 to -CA$0.26 for the same period. The Pharmaceuticals industry in Canada is expected to see a 23% decline in net income next year. The consensus price target was lowered from CA$1.29 to CA$1.28. Share price is up 16% to CA$0.47 over the past week.
お知らせ • Feb 18The Flowr Corporation Requests to Delist from the TSX Venture ExchangeThe Flowr Corporation (the “Company”) announced that in connection with the closing of its previously announced sale transaction under the Companies’ Creditors Arrangement Act (Canada) (the “CCAAProceedings”), all of the former officers and directors of the Company have resigned and the Court has expanded the powers of Ernst & Young Inc., which acts as the Court appointed Monitor under the CCAA Proceedings (the “CCAA Monitor”) in order to oversee the remaining activities in the CCAA Proceedings including any distribution to creditors and the winding down of operations. On account of the Company having no operating business and having sold substantially all of its assets, as well as the resignation of its management and board of directors, the CCAA Monitor has requested that the common shares of the Company be delisted from the TSX Venture Exchange.
お知らせ • Feb 04Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 5.12 million.1000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million on November 1, 2022. The transaction is subject to approval by the Ontario Superior Court of Justice,receipt of regulatory approval, the Stalking Horse Purchase Agreement being determined to be the successful bid in the SISP and the Court granting both an order approving the Stalking Horse Purchase Agreement and an Approval and Vesting Order. In the event the Purchaser is not the winning bidder under any such auction, the Stalking Horse Purchase Agreement will be terminated, and the Purchaser will be entitled to payment of a break-up fee in the amount of CAD 0.185 million following closing of the winning bid. The Purchase Price will be satisfied through (a) a credit bid of the DIP Loan in a principal amount of CAD 2 million, plus the Closing DIP Amount, if any, and any accrued and unpaid interest, expenses, fees and other amounts thereon, (b) a cash amount equal to the Purchase Price less the Credit Bid in cash, a portion of which may be payable in non-cash consideration in certain circumstances, and (c) the assumption of the Assumed Liabilities. On December 1, 2022 1000343100 Ontario Inc. has entered into a definitive purchase agreement to acquire all of the issued and outstanding shares in the capital of The Flowr Group (Okanagan) Inc. The purchase price payable by 1000343100 Ontario Inc. for the Purchased Shares pursuant to the Purchase Agreement shall be CAD 5,115,000, being equal to (a) CAD4,015,000, and (b) common shares in the capital of Avant with a value of CAD 1.1 million based on the deemed price per Avant Share equal to a 15% discount to the volume weighted average price per Avant Share on the Toronto Stock Exchange for the 10 consecutive trading days preceding the close of trading on the trading day before the Closing Date. The Transaction is expected to close within Q1 of 2023. Jane Dietrich, Jeremy Bornstein, Jeffrey Mikelberg, Kori Williams, Chandimal Nicholas, Jonathan Sherman of Cassels is representing Avant. Avant Brands K1 Inc. (formerly 1000343100 Ontario Inc.) completed the acquisition of The Flowr Group (Okanagan) Inc. from The Flowr Corporation (TSXV:FLWR.H) for CAD 7.7 million on February 3, 2023. The aggregate revised purchase price consists of (a) CAD 3.85 million payable in cash and (b) 7,402,186 common shares in the capital of Avant; plus (i) the amount of the Closing DIP Loan (to the extent not otherwise repaid), to an aggregate of CAD 2.5 million; and (ii) the value of the Assumed Liabilities, subject to certain adjustments (collectively, the “Purchase Price”). On January 31, 2023, the DIP Term Sheet was amended and the principal amount of the DIP Loan was increased by CAD 0.5 million to an aggregate of CAD 2.5 million.
お知らせ • Nov 021000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million.1000343100 Ontario Inc. entered into a Stalking Horse Purchase Agreement to acquire The Flowr Group (Okanagan) Inc from The Flowr Corporation (TSXV:FLWR.H) for CAD 0.89 million on November 1, 2022. The transaction is subject to approval by the Ontario Superior Court of Justice,receipt of regulatory approval, the Stalking Horse Purchase Agreement being determined to be the successful bid in the SISP and the Court granting both an order approving the Stalking Horse Purchase Agreement and an Approval and Vesting Order. In the event the Purchaser is not the winning bidder under any such auction, the Stalking Horse Purchase Agreement will be terminated, and the Purchaser will be entitled to payment of a break-up fee in the amount of CAD 0.185 million following closing of the winning bid. The Purchase Price will be satisfied through (a) a credit bid of the DIP Loan in a principal amount of CAD 2 million, plus the Closing DIP Amount, if any, and any accrued and unpaid interest, expenses, fees and other amounts thereon, (b) a cash amount equal to the Purchase Price less the Credit Bid in cash, a portion of which may be payable in non-cash consideration in certain circumstances, and (c) the assumption of the Assumed Liabilities.
お知らせ • Oct 18The Flowr Corporation Announces Resignation of Stephen Arbib as DirectorThe Flowr Corporation announced that Stephen Arbib has resigned from the board of directors of the Company effective immediately.
お知らせ • Oct 01The Flowr Corporation Announces the Resignation of Joanne Lee from the Board of DirectorsThe Flowr Corporation announced that Joanne Lee has resigned from the board of directors in order to pursue other opportunities.
Board Change • Sep 24High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Director Tom Flow is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Aug 11+ 1 more updateThe Flowr Corporation Announces Management ChangesThe Flowr Corporation announced leadership and governance changes with the appointments of Darren Karasiuk to the role of Chief Executive Officer and Director and the additions of Stephen Arbib as Chairman and Marvin Singer to the Board of Directors. Tom Flow, who has acted as Interim CEO of Flowr since March, remains on the Board along-side incumbents Joanne Lee and Ryan Roebuck. Darren is a veteran of the cannabis industry with experience and success in all aspects of the value chain. Prior to joining Flowr, Darren was CEO of Nova Cannabis, one of Canada’s larger cannabis retailers, disrupting the industry with the launch of the Value Buds banner. Prior to Nova, Darren was Chief Commercial Officer at Aurora Cannabis, leading it to become market share leader in Canada’s recreational and medical markets as well as in Europe. Before joining Aurora, Darren was VP Strategy and later SVP and GM, Recreational for MedReleaf, a Canadian LP sold to Aurora in 2018. Stephen Arbib is a Canadian entrepreneur, philanthropist and significant shareholder of Flowr. Mr. Arbib is the founder?and CEO of Momentum Solutions, one of the world’s leading logistics and life support service providers, specializing in humanitarian and emergency operations for government agencies, militaries and non-profit organizations. Momentum provides services from passenger and cargo air movements, freight forwarding, construction equipment leasing, labour force and staffing and housing. In 2013, Mr. Arbib founded?MedReleaf, the first ISO 9001 certified cannabis producer in North America and one of the global leaders in the production and research of medicinal cannabis which was sold to Aurora for CAD 3.2Bn in 2018. Mr. Arbib is the Director of the Arbib Foundation, a charitable foundation that allocates personal funds to charities across the globe. Marvin Singer currently works as a director and corporate consultant. Mr. Singer has acted as a consultant to private and public companies since January 2020, after retiring from practising corporate and securities law for 40 years, most recently as a senior partner in the international law firm of Norton Rose Fulbright Canada LLP from 2005 until 2019. Mr. Singer has extensive experience in equity and debt financings, governance, and mergers and acquisitions. Mr. Singer served as a director for Nova Cannabis and is currently a director of Osino Resources Corp. and Psyence Group Inc.
お知らせ • Jul 29Hawthorne Canada Limited completed the acquisition of KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR).Hawthorne Canada Limited entered into an agreement to acquire KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR) for CAD 16 million on February 16, 2022. The consideration will be paid as follows: 1) an initial cash payment of CAD 3.0 million; 2) full extinguishment of the principal amount outstanding under the existing loan agreement between Flowr and Hawthorne for the construction of the KRS Facility on closing, currently at approximately CAD 12 million; and 3) the balance of the purchase price paid in cash upon closing. The KRS Sale is expected to close in Q2 2022 and is subject to certain closing conditions, including receipt of all necessary regulatory and third-party approvals. The Flowr Corporation (TSXV:FLWR) completed the acquisition of KRS Facility in Kelowna on July 27, 2022. The Company is using the proceeds from the sale of this non-core asset to reduce the outstanding principal debt under its ATB led credit facility to CAD 1 million.
お知らせ • Jul 13The Flowr Corporation Announces Resignation of Noel Biderman as DirectorThe Flowr Corporation announces the resignation of Noel Biderman from the Board of Directors who is departing in order to pursue other opportunities.
お知らせ • Jul 05The Flowr Corporation Announces Resignation of DirectorsThe Flowr Corporation announced the resignation of Maurice Levesque and Don Duet from the Board of Directors who are departing in order to pursue other opportunities.
お知らせ • Jul 01The Flowr Corporation, Annual General Meeting, Sep 07, 2022The Flowr Corporation, Annual General Meeting, Sep 07, 2022.
お知らせ • Jun 24The Flowr Corporation Announces Headcount ReductionThe Flowr Corporation announced the completion of a significant corporate headcount reduction resulting in over $4 million in cost savings per year as well as an agreement to sell a non-core asset for aggregate gross proceeds of $3.4 million. The Company has completed a headcount reduction necessary in order to flatten its organizational structure and right-size SG&A with revenue. The Company has eliminated 40% of its workforce, largely in senior and middle management, resulting in an anticipated annual savings of over $4 million.
Reported Earnings • Jun 01First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: CA$0.01 loss per share (up from CA$0.025 loss in 1Q 2021). Revenue: CA$3.46m (down 9.7% from 1Q 2021). Net loss: CA$5.37m (loss narrowed 35% from 1Q 2021). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 188%. Over the next year, revenue is forecast to grow 25%, compared to a 92% growth forecast for the industry in Canada.
Price Target Changed • May 31Price target decreased to CA$0.04Down from CA$0.08, the current price target is provided by 1 analyst. New target price is 11% below last closing price of CA$0.045. Stock is down 86% over the past year. The company posted a net loss per share of CA$0.23 last year.
Board Change • May 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 31The Flowr Corporation Announces Impairment Charges for the First Quarter Ended March 31, 2022The Flowr Corporation announced impairment charges for the first quarter ended March 31, 2022. For the period, the company recorded impairment charges totaling CAD 29,000.
お知らせ • May 21The Flowr Corporation Announces Impairment Charges for the Fourth Quarter Ended December 31, 2021The Flowr Corporation announced impairment charges for the fourth quarter ended December 31, 2021. For the period, the company reported Impairment of assets of CAD 57,096,000 compared to CAD 83,979,000 a year ago.
お知らせ • May 03+ 1 more updateCannahealth Limited completed the acquisition of Holigen Limited from The Flowr Corporation (TSXV:FLWR).Cannahealth Limited entered into a definitive agreement to acquire Holigen Limited from The Flowr Corporation (TSXV:FLWR) for CAD 33.3 million on April 19, 2022. Under the transaction, Cannahealth will acquire 1200 shares of Holigen and the receivables owed by Holigen Limited to The Flowr Corporation. The total consideration payable is approximately CAD 35 million consisting of CAD 3.75 million in cash, 1.9 common shares in the capital of Akanda Corp. (NasdaqCM:AKAN), parent of Cannahealth and the indirect assumption of RPK’s indebtedness of approximately CAD 5.1 million. The purchase price will be paid on the closing date, and it was agreed that CAD 1.00 of the purchase price will allocated to the shares, and the balance of the purchase price will be allocated to the purchased receivables. In addition, at least CAD 0.834 million of interim funding will be provided by Cannahealth to Holigen which has already been received by Flowr. In a related transaction, Akanda has agreed to subscribe for CAD 1 million of common shares in the capital of Flowr at a price per share of CAD 0.07 per share. As part of the transaction, Flowr has agreed to provide transition services to Akanda and Holigen for a period of at least 90 days after the closing of the transaction. The transaction is subject to regulatory approvals. The transaction was overseen by an independent committee of directors of Flowr and was unanimously approved by the Independent Committee as well as the board of directors of each of Flowr and Akanda. At the closing of the transaction, which is expected to be in the second quarter of 2022. The deal would give Flowr a significant amount of cash on closing to solidify its balance sheet and also preserve the upside related to its European operations. Hyperion Capital Inc. acted as fairness opinion provider to the Independent Committee. In connection with the transaction, Holigen will pay an advisory fee to an arm’s length third party equal to 7% of the purchase price, 50% of which is payable in cash and 50% of which is payable in consideration shares to be received by Holigen. Eric Foster of Dentons Canada LLP acted as legal advisor for Akanda Corp. Jeff Hergott of Wildeboer Dellelce LLP acted as legal advisor for The Flowr Corporation. Cannahealth Limited completed the acquisition of Holigen Limited from The Flowr Corporation (TSXV:FLWR) on May 2, 2022.
Price Target Changed • Apr 27Price target decreased to CA$0.08Down from CA$0.10, the current price target is provided by 1 analyst. New target price is 45% above last closing price of CA$0.055. Stock is down 81% over the past year. The company is forecast to post a net loss per share of CA$0.08 next year compared to a net loss per share of CA$0.95 last year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Independent Director Maurice Levesque is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 21+ 1 more updateCannahealth Limited entered into a definitive agreement to acquire Holigen Limited from The Flowr Corporation (TSXV:FLWR) for CAD 34.1 million.Cannahealth Limited entered into a definitive agreement to acquire Holigen Limited from The Flowr Corporation (TSXV:FLWR) for CAD 34.1 million on April 19, 2022. The total consideration payable is approximately CAD 35 million consisting of: (i) CAD 3.5 million in cash; (ii) 1.9 common shares in the capital of Akanda currently valued at $10.30 (CAD 12.98) based on the closing price of the consideration shares on April 19, 2022; (iii) the indirect assumption by Akanda of RPK’s indebtedness of approximately CAD 5.1 million; and (iv) at least CAD 0.834 million of interim funding to Holigen which has already been received by Flowr. In addition, Akanda has agreed to subscribe for CAD 1 million of common shares in the capital of Flowr at a price per share of CAD 0.07 per share. As part of the transaction, Flowr has agreed to provide transition services to Akanda and Holigen for a period of at least 90 days after the closing of the transaction. The transaction is subject to regulatory approvals. The transaction was overseen by an independent committee of directors of Flowr and was unanimously approved by the Independent Committee as well as the board of directors of each of Flowr and Akanda. At the closing of the transaction, which is expected to be in the second quarter of 2022. The deal would give Flowr a significant amount of cash on closing to solidify its balance sheet and also preserve the upside related to its European operations. Hyperion Capital Inc. acted as fairness opinion provider to the Independent Committee. In connection with the transaction, Holigen will pay an advisory fee to an arm’s length third party equal to 7% of the purchase price, 50% of which is payable in cash and 50% of which is payable in consideration shares to be received by Holigen.
お知らせ • Feb 19Hawthorne Canada Limited entered into an agreement to acquire KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR) for $16 million.Hawthorne Canada Limited entered into an agreement to acquire KRS Facility in Kelowna from The Flowr Corporation (TSXV:FLWR) for $16 million on February 18, 2022. The consideration will be paid as follows: 1) an initial cash payment of $3.0 million; 2) full extinguishment of the principal amount outstanding under the existing loan agreement between Flowr and Hawthorne for the construction of the KRS Facility on closing, currently at approximately $12 million; and 3) the balance of the purchase price paid in cash upon closing. The KRS Sale is expected to close in Q2 2022 and is subject to certain closing conditions, including receipt of all necessary regulatory and third-party approvals.
Major Estimate Revision • Dec 06Consensus revenue estimates fall to CA$12.0mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CA$14.0m to CA$12.0m. Forecast losses increased from -CA$0.34 to -CA$0.36 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$0.10 unchanged from last update. Share price fell 24% to CA$0.065 over the past week.
Reported Earnings • Dec 01Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2021 results: CA$0.02 loss per share (up from CA$0.073 loss in 3Q 2020). Net loss: CA$8.77m (loss narrowed 9.7% from 3Q 2020). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 100%. Earnings per share (EPS) surpassed analyst estimates by 100%. Over the next year, revenue is forecast to grow 149%, compared to a 140% growth forecast for the industry in Canada.
Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$7.20m (loss widened 47% from 2Q 2020).
お知らせ • Aug 21+ 1 more updateHealth Canada Grants a Research License to The Flowr CorporationThe Flowr Corporation announced that it has been granted a research license by Health Canada. The research license allows the Company to distribute and administer its cannabis for research purposes and to test and review its products based on taste, sight, smell and touch. The Company will utilize this research license in the research and development of novel product offerings.
お知らせ • Jul 20The Flowr Corporation announced that it has received CAD 7.014 million in fundingOn July 19, 2021, The Flowr Corporation (TSXV:FLWR) closed the transaction.
お知らせ • Jul 16The Flowr Corporation announced that it expects to receive CAD 7.014 million in fundingThe Flowr Corporation announced a private placement of 33,400,000 units at a price of CAD 0.21 per unit for gross proceeds of CAD 7,014,000 on July 15, 2021. Each unit will consist of one common share and one common share purchase warrant, Each warrant will be exercisable into one common share at an exercise price of CAD 0.26 per warrant share at any time for a period of 42 months following the closing date of the transaction. The company will pay CAD 490,000 as finders' fees and issue 2,000,400 broker warrants. Each broker warrant will be exercisable into one unit at the issue price for a period of 36 months from the closing of the transaction. The transaction is expected to close on or about July 20, 2021, subject to the satisfaction of customary closing conditions and the receipt of regulatory approvals, including the approval of the TSX Venture Exchange. The comapny entered into a securities purchase agreement with a purchaser.
Price Target Changed • Jul 15Price target decreased to CA$0.68Down from CA$0.97, the current price target is an average from 2 analysts. New target price is 200% above last closing price of CA$0.23. Stock is down 58% over the past year.
お知らせ • Apr 29Rodeo Capital Limited entered into an agreement to acquire TCann Pty Ltd. from The Flowr Corporation (TSXV:FLWR) for AUD 0.50 million.Rodeo Capital Limited entered into an agreement to acquire TCann Pty Ltd. from The Flowr Corporation (TSXV:FLWR) for AUD 0.50 million on April 28, 2021. Hyperion Capital Inc. acted as financial advisor to The Flowr Corporation.
お知らせ • Mar 17The Flowr Corporation has completed a Composite Units Offering in the amount of CAD 15.3 million.The Flowr Corporation has completed a Composite Units Offering in the amount of CAD 15.3 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 30,000,000 Price\Range: CAD 0.51 Discount Per Security: CAD 0.0357 Transaction Features: Regulation S
Is New 90 Day High Low • Mar 06New 90-day low: CA$0.31The company is down 37% from its price of CA$0.49 on 04 December 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 30% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.00 per share.
Is New 90 Day High Low • Feb 11New 90-day high: CA$0.60The company is up 33% from its price of CA$0.45 on 12 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 109% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.22 per share.
お知らせ • Feb 05The Flowr Corporation Partners with ROSE Lifescience IncThe Flowr Corporation announced that it has entered the Province of Quebec with its first commercial orders for its BC Pink Kush and its new strain BC Black Cherry. Flowr has shipped dried cannabis flower for the first time into the Quebec market through a distribution partnership with ROSE LifeScience Inc. (“ROSE”). Flowr entered into a Sales, Marketing and Distribution Agreement with ROSE in April 2020 and obtained its Autorité des marchés publics approval to operate in the Province of Quebec in August 2020.
お知らせ • Jan 24The Flowr Corporation announced that it expects to receive CAD 1 million in fundingThe Flowr Corporation (TSXV:FLWR) announced a non-brokered private placement of 3,333,333 common shares at a price of CAD 0.3 per share for gross proceeds of up to CAD 1,000,000 led by certain directors, officers and insiders on January 22, 2021. The transaction is subject to approval of the TSX Venture Exchange.
分析記事 • Jan 18Flowr's (CVE:FLWR) Stock Price Has Reduced 79% In The Past YearIt's not a secret that every investor will make bad investments, from time to time. But serious investors should think...
お知らせ • Jan 06Flowr and Hawthorne Canada Jointly Announce the Completion of the World’S First Cannabis Research and Development Facility of Its KindNorth America’s first research and development facility dedicated to advancing cannabis cultivation techniques and systems has been completed by The Flowr Corporation and Hawthorne Canada Limited . Hawthorne is a subsidiary of the Hawthorne Gardening Company division of The Scotts Miracle-Gro Company. Scotts Miracle-Gro is the world’s leading marketer of branded consumer lawn and garden products and indoor growing solutions. Flowr cultivates and sells premium cannabis to medical and adult-use markets in Canada, Europe and Australia.
Is New 90 Day High Low • Jan 01New 90-day low: CA$0.33The company is down 22% from its price of CA$0.41 on 02 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 60% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$4.55 per share.
お知らせ • Dec 26The Flowr Corporation Announces CEO ChangesThe Flowr Corporation announced In 2021, Vinay Tolia, Chief Executive Officer of Flowr, will be stepping down from his role as Chief Executive Officer and will be relocating to the United States for personal reasons. He will stay with the Company through the end of February to ensure a smooth transition. Mr. Tolia will remain on the Board of Directors. The current President of Flowr, Lance Emanuel, will lead the Company as Interim Chief Executive Officer. Lance Emanuel joined Flowr in January 2019. Lance has been building seed and early-stage companies into multi-million-dollar enterprises while overseeing critical aspects of business operations in highly regulated markets for more than a decade. He has a wealth of experience in the management of sales, marketing, product management, R&D, technology, legal, compliance and regulatory affairs as well as in procuring both debt and equity financing and creating large scale strategic partnerships. He holds a BBA, with distinction, from the University of Michigan’s Ross School of Business and a Juris Doctor from the Benjamin N. Cardozo School of Law in New York City.
お知らせ • Dec 25+ 1 more updateThe Flowr Corporation Announces Board AppointmentThe Flowr Corporation announced announce new appointments to the Board of Directors which include Jörg Cieslok, Michael Galego, Vincent Gasparro and Joanne Lee. In addition, Stephen Arbib, Jonathan Goldman and Francisco Ortiz von Bismarck have been appointed as observers to the Board of Directors. The Board of Directors will continue to be led by current Chairman of the Board & Chief Strategist, Steve Klein. These new appointees join the following directors: Steve Klein (Chair), Vinay Tolia, Thomas Flow, Don Duet and Maurice Levesque. Jörg Cieslok is an executive with few peers in the world of out-of-home media. Known for his industry foresight, out-of-the-box thinking, and sales and marketing strategy, Mr. Cieslok has changed the landscape of out-of-home media in Canada over the course of a 30-year career. By embracing creativity and innovation, he takes advertising campaigns from conceptual ideas to experiential media placements. Jörg was the recipient of the prestigious 2017 CVCA Private Equity deal of the year award for the sale of Cieslok Media to Bell Media. Michael Galego is an executive, lawyer and corporate director with extensive M&A and corporate finance experience. Mr. Galego is currently CEO of Apolo Capital Advisory Corp. and sits on the board of directors of several public and private companies. Mr. Galego was a co-founder and director of ICC Labs Inc. and was integral in its sale to Aurora Cannabis Inc. in November 2018. Vincent Gasparro is currently the Managing Director, Corporate Development & Clean Energy Finance, at Vancity Community Investment Bank. From November 2018 to March 2020, he was the Principal Secretary in the Office of the Mayor of Toronto where he had specific public policy responsibilities including matters related to Toronto Hydro, Toronto Parking Authority, Toronto Global, Toronto Community Housing, CreateTo and the Toronto Police Service. Joanne Lee is a seasoned business executive with strong Operations, Logistics and Procurement expertise, underpinned by extensive financial and M&A experience. She has held key roles in the Healthcare, Consumer Packaging, Polymer and Chemical sectors. As a proven organizational change leader, Ms. Lee has led teams through challenging turnarounds as well as significant business enhancements that have led to increased profitability. Ms. Lee joined Premier Candle Corporation (PCC) in 2009 as General Manager leading the corporation’s division.
お知らせ • Dec 19The Flowr Corporation Announces Strategic Warehousing Agreement with Tilray, IncThe Flowr Corporation announced strategic warehousing agreement with Tilray, Inc. whereby the parties have agreed to the storage and warehousing of E.U. GMP certified medical cannabis at the Company's Sintra facility in Portugal. The parties will undertake to develop a collaborative approach with a view to leverage each party's E.U. GMP certified facilities in Portugal to store and warehouse medicinal cannabis products for the European market. The commercial terms of the agreement were not disclosed.
Is New 90 Day High Low • Dec 12New 90-day low: CA$0.35The company is down 26% from its price of CA$0.48 on 11 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 49% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$8.06 per share.
Price Target Changed • Dec 05Price target lowered to CA$1.15Down from CA$1.29, the current price target is an average from 4 analysts. The new target price is 135% above the current share price of CA$0.49. As of last close, the stock is down 77% over the past year.
Major Estimate Revision • Dec 01Analysts lower revenue estimates to CA$9.21mThe 2020 consensus revenue estimate decreased from CA$11.7m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -CA$0.22 to -CA$0.26 for the same period. The Pharmaceuticals industry in Canada is expected to see a 23% decline in net income next year. The consensus price target was lowered from CA$1.29 to CA$1.28. Share price is up 16% to CA$0.47 over the past week.
Reported Earnings • Nov 27Third quarter 2020 earnings released: CA$0.07 loss per shareThird quarter 2020 results: Net loss: CA$9.72m (loss narrowed 36% from 3Q 2019).
Analyst Estimate Surprise Post Earnings • Nov 27Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 0.1%. Earnings per share (EPS) exceeded analyst estimates by 133%. Over the next year, revenue is forecast to grow 600%, compared to a 136% growth forecast for the Pharmaceuticals industry in Canada.
分析記事 • Nov 26The Flowr Corporation (CVE:FLWR) Analysts Are More Bearish Than They Used To BeToday is shaping up negative for The Flowr Corporation (CVE:FLWR) shareholders, with the analysts delivering a...
お知らせ • Nov 17The Flowr Corporation to Report Q3, 2020 Results on Nov 24, 2020The Flowr Corporation announced that they will report Q3, 2020 results on Nov 24, 2020
お知らせ • Oct 27Andrew Teehan to Leave The Flowr Corporation as General Counsel, Effective October 28, 2020The Flowr Corporation announced that Andrew Teehan its General Counsel is leaving the Company on October 28, 2020 to pursue an opportunity outside of the cannabis industry.
Price Target Changed • Oct 21Price target lowered to CA$1.45Down from CA$1.70, the current price target is an average from 4 analysts. The new target price is 205% above the current share price of CA$0.47. As of last close, the stock is down 82% over the past year.
Is New 90 Day High Low • Oct 01New 90-day low: CA$0.39The company is down 32% from its price of CA$0.57 on 03 July 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CA$8.02 per share.
お知らせ • Aug 19The Flowr Corporation to Report Q2, 2020 Results on Aug 26, 2020The Flowr Corporation announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 26, 2020
分析記事 • Jul 21How Many The Flowr Corporation (CVE:FLWR) Shares Did Insiders Buy, In The Last Year?We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...